Leerink Partners analyst Mani Foroohar assigned a Sell rating on Moderna (MRNA – Research Report) on November 7 and set a price target of ...

The Cambridge-based company’s latest COVID shot was approved three weeks earlier than last year, according to a statement ...

Moderna Inc.’s stock jumped 5% early Thursday, after the company’s third-quarter earnings showed an unexpected profit and ...

Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...

Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...

Stephane Bancel is stepping down as chief commercial officer of Moderna Inc., according to a person familiar with the matter.

Moderna shares jumped after the biotechnology company reported higher-than-expected sales of its Covid-19 vaccine and backed ...

Moderna reported earnings that exceeded expectations due to effective cost management but still has challenges related to its ...

Heading into Moderna’s third-quarter earnings, investors and analysts will be watching to see how the Cambridge drugmaker ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Lab developer Alexandria Real Estate Partners will sell the Moderna Technology Center in Norwood to the vaccine manufacturer ...

Barclays lowered the firm’s price target on Moderna (MRNA) to $111 from $125 and keeps an Overweight rating on the shares. The ...